Short-term tumor marker levels [carcinoembryonic antigen [CEA] and carbohydrate antigen 19-9 [CA19-9]] were assessed as exploratory endpoints, measured preoperatively and at three months postoperatively, with recurrence or metastasis events recorded within the same period.<h4>Results</h4>The IPC procedure was successfully completed in all assigned patients, confirming procedural feasibility. The gene discussed is CEACAM5; the disease is neoplasm.